



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/662,052	09/15/2000	Dangsheng Li	5986/1G098-US1	4993	
7	590 07/10/2003				
Darby & Darby PC			· EXAM	EXAMINER	
805 Third Avenue New York, NY 10022			SOUAYA, JI	EHANNE E	
			ART UNIT	PAPER NUMBER	
	•		1634	15	
		DATE MAILED: 07/10/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
A	09/662,052	LI ET AL.			
Notice of Allowability	Examiner	Art Unit			
·	Jehanne E Souaya	1634			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.					
<ol> <li>This communication is responsive to NA.</li> <li>The allowed claim(s) is/are 1-9.</li> <li>The drawings filed on are accepted by the Examiner.</li> <li>Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).         <ul> <li>All b)</li></ul></li></ol>					
<ul> <li>* Certified copies not received:</li> <li>5. ☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).</li> <li>(a) ☐ The translation of the foreign language provisional application has been received.</li> <li>6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>					
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. <b>THIS THREE-MONTH PERIOD IS NOT EXTENDABLE</b> .					
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.					
<ul> <li>8.  ☐ CORRECTED DRAWINGS must be submitted.</li> <li>(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) ☐ hereto or 2) ☐ to Paper No. <u>7</u>.</li> <li>(b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner.</li> </ul>					
(c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No					
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet.					
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.					
Attachment(s)					
<ul> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statements (PTO-1449), Paper No</li> <li>Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> </ul>	4⊠ Interview Sum 6⊠ Examiner's Ar	mal Patent Application (PTO-152) mary (PTO-413), Paper No nendment/Comment . atement of Reasons for Allowance			
·					

Application/Control Number: 09/662,052

Art Unit: 1634

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Howard Frankfort on June 30, 2003.

The application has been amended as follows:

Claim 1 (three times amended) An isolated nucleic acid molecule [comprising a nucleotide sequence] consisting of the nucleotide sequence of SEQ ID NO: 3, wherein the nucleic acid molecule [sequence] encodes a functional NRIF3 nuclear hormone receptor coactivator polypeptide, wherein the NRIF3 binds in a ligand dependent manner to thyroid hormone receptor (TR) and retinoid X receptor (RXR), but does not interact with retinoic acid receptor (RAR), vitamin D receptor (VDR), progesterone receptor (PR), glucocorticoid receptor (GR), and estrogen receptor (ER) in a yeast two hybrid assay system, or *in vitro*, or both, which polypeptide contain an LXXIL (SEQ ID NO: 2) module in its C-terminal domain.

Claim 3 (twice amended) An isolated nucleic acid <u>molecule</u> [sequence] comprising the [a] nucleotide sequence [consisting] of SEQ ID NO: 3 (Figure 2).

Claim 4 (twice amended) A vector comprising the nucleic acid <u>molecule</u> [sequence] according to claim 3, wherein said nucleic acid <u>molecule</u> [sequence] is operatively associated with an expression control sequence.

Art Unit: 1634

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Souaya whose telephone number is (703) 308-6565. The examiner can normally be reached Monday-Friday from 9:00 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jehanne Souaya Primary Examiner Art Unit 1634

gehanne Souaga